The majority shareholders of Veloxis Pharmaceuticals (“Veloxis”) have undertaken to accept a conditional, voluntary public offer from Asahi Kasei Pharma Denmark.
The offer to purchase all of the issued and outstanding shares and warrants in Veloxis corresponds to a total price of approx. DKK 8.9bn if all shares are sold and all warrants are acquired.
Veloxis is a specialty pharmaceutical company committed to improving the lives of transplant patients. The shares in Veloxis are admitted to trading and official listing on Nasdaq Copenhagen. Lundbeckfond Invest and Novo Holdings each holds more than 40% of the shares in Veloxis.
Asahi Kasei Pharma Denmark is a subsidiary of Asahi Kasei Corporation, a Japanese public corporation listed on the Tokyo Stock Exchange. The group comprises several companies within the health care sector, including the hospitals.
Veloxis’ board of directors has unanimously resolved to recommend that the shareholders of Veloxis vote to accept the offer.
Accura has advised Lundbeckfond Invest in connection with the transaction.